# REGENXBIO share price today (REGENXBIO Inc., RGNX)

> REGENXBIO Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. RGNX · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/rgnx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $7.71 (−31.2% in a year)
- Revenue (Jun 2026): $108 M (+405.7% on a year ago)
- Profit (Jun 2026): $22.7 M
- Operating margin: 27.1% (+323.4 points on a year ago)
- ROE: −189%, FY25
- ROIC: −97.8%, against a 11.7% cost of capital: −109.5 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the REGENXBIO share price today? REGENXBIO Inc.'s share price was $7.71 at the close on 4 November 2026. It has been falling for 11 weeks. That is 15.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $15, and at that close it sat 22% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 10 years the share price moved −5% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does REGENXBIO pay? REGENXBIO Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is REGENXBIO on? REGENXBIO is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is REGENXBIO profitable? REGENXBIO Inc. earned $22.7 M of net profit in the Jun 2026 quarter. The full FY25 year was a loss of $194 M. That is 21.0% of the quarter's revenue. The same quarter a year earlier lost $70.9 M. 10 of the last 12 reported quarters were loss-making. ## How much revenue does REGENXBIO make, and is it growing? REGENXBIO Inc. reported $108 M of revenue in the Jun 2026 quarter, +405.7% on the same quarter a year earlier. Over 4 years it has grown −22.4% a year on average. The last full year, FY25, came in at $170 M. The last four reported quarters add to $174 M. FY25 revenue was $170 M, +104.5% on the year before. Recent pace: the last four quarters grew +94.7% on average, against −22.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.0%, against +40.0% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does REGENXBIO keep? REGENXBIO Inc.'s operating margin was 27.1% in the Jun 2026 quarter, 323.4 percentage points higher than the same quarter a year ago. Across 5 years it has been between −293.0% and 34.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +323.4 percentage points on the year while gross margin changed +250.1 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is REGENXBIO's profit turning into cash? REGENXBIO Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $124 M of cash, against −$194 M of profit. After $2.4 M of spending on assets, free cash was −$126 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does REGENXBIO's cash go? REGENXBIO Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $14.8 M on assets over the last 3 years. Averaged over those years that is 2.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $14.8 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is REGENXBIO's P/E ratio, and how does it compare with its own history? REGENXBIO Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values REGENXBIO Inc. at 3.0× its FY25 revenue of $170 M. The P/E comes back here once profit turns positive. ## Is the REGENXBIO business getting better or worse? REGENXBIO Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does REGENXBIO earn on its capital? REGENXBIO Inc. earned a ROE of −189% in FY25. Its return on capital used (ROIC) is 109.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −113.8% net margin and 0.38× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −113.8% net margin × 0.38× asset turnover × 4.41× leverage (assets divided by equity) ≈ −190.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −97.8% − 11.7% = −109.5 percentage points. The 11.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −97.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −107.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does REGENXBIO have too much debt? REGENXBIO Inc. has total debt of $250 M against shareholder equity of $71.8 M as of Jun 2026, so its debt is 3.49× its equity. Year by year, that ratio went from 0.34 in FY21 to 2.54 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the REGENXBIO shareholding pattern? 17.6% of REGENXBIO Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is REGENXBIO from balance-sheet trouble? For REGENXBIO Inc., the Z-score is −3.82. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −3.82 is inside the danger zone, so the balance sheet is a real risk. ## How does REGENXBIO rank in its industry? There is no score against its industry: REGENXBIO Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is REGENXBIO compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to REGENXBIO in size? REGENXBIO is the 143rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Capricor Therapeutics, Inc., Shattuck Labs, Inc. and CytomX Therapeutics, Inc. Just below it: YD Bio, Arvinas, Inc. and Gyre Therapeutics, Inc. ### Biotechnology companies close in size

1. [Capricor Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/capr) $519 million
2. [Shattuck Labs, Inc.](https://www.sectoralpha.in/us/stocks/sttk) $517 million
3. [CytomX Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ctmx) $512 million
4. REGENXBIO Inc. $509 million
5. [YD Bio Limited](https://www.sectoralpha.in/us/stocks/ydes) $492 million
6. [Arvinas, Inc.](https://www.sectoralpha.in/us/stocks/arvn) $486 million
7. [Gyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/gyre) $471 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Investors Title Company](https://www.sectoralpha.in/us/stocks/itic) $504 million · Insurance - Specialty
2. [TAT Technologies Ltd.](https://www.sectoralpha.in/us/stocks/tatt) $504 million · Aerospace & Defense
3. REGENXBIO Inc. $504 million
4. [Hallador Energy Company](https://www.sectoralpha.in/us/stocks/hnrg) $502 million · Utilities - Independent Power Producers
5. [Citizens & Northern Corporation](https://www.sectoralpha.in/us/stocks/cznc) $502 million · Banks - Regional

## What else do people ask about REGENXBIO? ### What were REGENXBIO's latest quarterly results? REGENXBIO Inc. reported revenue of $108 M and net profit of $22.7 M for the Jun 2026 quarter. Earnings per share were $0.43. The operating margin was 27.1%, 323.4 percentage points higher than a year earlier (as of 4 November 2026). ### What is REGENXBIO's market cap? REGENXBIO Inc.'s market capitalisation is $509 M at a stock price of $7.71. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is REGENXBIO performing? REGENXBIO Inc.'s share price has been falling for 11 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will REGENXBIO's stock price go up? This page does not forecast REGENXBIO Inc.'s stock price. What it shows instead: the stock price is $7.71, and it has been falling for 11 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is REGENXBIO in its business cycle? REGENXBIO Inc.'s FY25 operating margin was −94.6%, against a 5-year range of −293.0% to 34.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 27.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the REGENXBIO story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is REGENXBIO a stock worth studying right now? What the numbers show: REGENXBIO Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.